Dermal Coverage of Traumatic War Wounds

Abstract

The proposed study is a prospective, randomized within-patient controlled feasibility study to evaluate the safety and effectiveness of the ReCell Device for re-epithelialization of full thickness wounds treated with INTEGRA MBWM. The ReCell Device is a stand-alone, battery operated cell separation device that enables preparation of a cell suspension from a small, thin, split-thickness skin biopsy. The autologous epidermal cell suspension is available for immediate delivery onto a prepared skin surface. This process has the potential to enhance skin regeneration while minimizing donor site morbidity2,3. The performance of ReCell over INTEGRA MBWM in combination with 1:6 meshed split-thickness skin graft (STSG) will be compared to standard practice control (i.e., 1:1.5 meshed STSG over Integra MBWM). We expect all ReCell-treated and control areas of the wounds to heal adequately. However, we predict areas treated with ReCell will re-epithelialize more quickly than control areas, which has the potential to reduce the risk of infection and scarring in ReCell-treated areas compared to control areas.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2017
Accession Number
AD1047259

Entities

People

  • Leon Nesti

Organizations

  • Geneva Foundation

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Agreements
  • Biomedical Research
  • Blood Chemistry
  • Burns
  • Chemical Burns
  • Feasibility Studies
  • Histology
  • Infection
  • Medical Personnel
  • Military Medicine
  • Monitoring
  • Safety
  • Skin Grafts
  • Standards
  • Surgery
  • Thickness
  • Wound Infections

Fields of Study

  • Medicine

Readers

  • Plasma Physics.
  • Trauma Surgery or Emergency Medicine.